Business research

GeniPhys Inc Receives $974,000 Commercial Research Grant Over Two Years | Business

WEST LAFAYETTE – GeniPhys Inc., a life sciences company focused on the development and commercialization of proprietary biopolymer technology developed in the lab of Professor Sherry Harbin at Purdue University, has been awarded a research grant on the Small Business Innovation (SBIR) grant of $974,349 over two years from the National Science Foundation.

The core technology, known as Collymer, is a novel polymerizable collagen molecule that can be used to custom design and manufacture implantable materials to address unmet needs for the restoration and reconstruction of functional tissue, including breast tissue, skeletal muscle, cartilage, skin, voice box and more. This Phase II grant will be used to advance the commercialization of the company’s initial product, Collymer Self Assembling Scaffold (Collymer SAS).

Collymer materials exploit both the mechanical and biochemical signaling characteristics of natural collagen found in tissues. This allows the materials to support regenerative and restorative healing without rapidly degrading and causing inflammation or foreign body responses. This mechanism of action has been validated in multiple preclinical proof-of-concept studies. Additionally, Collymer is highly customizable, allowing the creation of materials with a variety of formats and mechanical properties.

GeniPhys has previously received a $225,000 NSF SBIR Phase I grant to perform preclinical testing to evaluate Collymer SAS prototypes for breast tissue restoration in a porcine lumpectomy model.

Working with members of Purdue’s Weldon School of Biomedical Engineering, Purdue’s College of Veterinary Medicine, and Indiana University School of Medicine, all project milestones were met.

Additionally, a peer-reviewed publication in the February 2021 issue of Scientific Reports resulted from this Phase I project, showcasing the translational potential of Collymer SAS as an easy-to-apply soft tissue filler that conforms to patient-specific defects and regenerates complex soft tissues. tissues in the absence of inflammation.

“We are honored to have been selected for this grant and are excited to be able to move Collymer SAS forward toward U.S. Food and Drug Administration submission and further commercialization,” said Andy Eibling, CEO of GeniPhys. . “We believe the Collymer platform will have a tremendous impact on patients around the world, and this grant is an important step in the process.”

Harbin, founder and chief scientific officer of GeniPhys, is a professor at Purdue’s Weldon School of Biomedical Engineering with a cross appointment in the Department of Basic Medical Sciences at Purdue’s College of Veterinary Medicine.

“Purdue has a long and successful track record in developing and translating innovative biomaterials targeting tissue regeneration,” said Harbin. “This next-generation technology provides a biopolymeric material that can be widely customized and harnesses the body’s ability to regenerate itself by keeping inflammation and immune mediators at bay.”

TJ Puls, who trained under Harbin, is now Head of Product Development for GeniPhys and Principal Investigator for the SBIR Phase II award.

“This grant will allow GeniPhys to scale its manufacturing capabilities for commercialization and file key regulatory submissions,” Puls said.

GeniPhys will initially pursue regulatory filings for the management and restoration of wounds and defects that affect the skin as well as other soft tissues, including breasts, skeletal muscle and adipose tissue. The company will explore the use of Collymer materials in other applications by leveraging strategic partnerships with innovative and industry-leading companies.